Table 1 Baseline demographics

From: Telemedicine-supported lifestyle intervention for glycemic control in patients with CHD and T2DM: multicenter, randomized controlled trial

Parameters

Lifestyle intervention group (n = 251)

Usual care (n = 248)

Sex

 Male

208 (82.9%)

210 (84.7%)

 Female

43 (17.1%)

38 (15.3%)

Age at inclusion (year)

68 (8)

68 (7)

Body mass index (kg m2)

30.2 (5.0)

30.0 (4.6)

Resting heart rate (beats per min)

68 (11)

71 (12)

Blood pressure (mm Hg)

 Systolic

137 (17)

138 (18)

 Diastolic

78 (10)

80 (10)

CHD and T2DM

 Duration of CHD (year)

9.3 (8.2)

8.2 (6.2)

 CHD classification

 no relevant stenosis (<50%)

46 (18.3%)

41 (16.5%)

 1 vessel disease

53 (21.1%)

62 (25.0%)

 2 vessel disease

47 (18.7%)

37 (14.9%)

 3 vessel disease

64 (25.5%)

74 (29.8%)

 Left main coronary disease

5 (2.0%)

4 (1.6%)

 Unknown

36 (14.3%)

29 (11.7%)

 CCS score

 Grade 0—no angina

208 (82.9%)

196 (79.0%)

 Grade I—angina only with strenuous physical activity

34 (13.5%)

39 (15.7%)

 Grade II—slight limitation of ordinary activity

7 (2.8%)

12 (4.8%)

 Grade III–IV—marked limitation of ordinary physical activity or inability to carry on any physical activity without discomfort

1 (0.4%)

1 (0.4%)

 Previous myocardial infarction

91 (36.3%)

80 (32.3%)

 Coronary revascularization

139 (55.4%)

135 (54.4%)

 Coronary artery bypass graft

38 (15.1%)

44 (17.7%)

 Duration of T2DM (year)

12.2 (8.9)

12.3 (7.9)

 HbA1c

 Percentage

6.8 (0.9)

6.9 (1.0)

 mmol mol−1

51 (9.8)

52 (10.9)

 <7.0% (<53 mmol mol−1)

165 (66%)

152 (61%)

 7.0–7.9% (53–63 mmol mol−1)

57 (23%)

65 (26%)

 ≥8.0% (≥64 mmol mol−1)

26 (10%)

31 (13%)

 Number of oral antidiabetic agents

 0

42 (16.7%)

42 (16.9%)

 1

97 (38.6%)

108 (43.5%)

 2

82 (32.7%)

75 (30.2%)

 ≥3

30 (12.0%)

22 (8.9%)

 Patients treated with insulin

73 (29.1%)

64 (25.8%)

Other cardiovascular risk factors and diseases

 Hypertension

233 (92.8%)

228 (91.9%)

 Hyperlipidemia

216 (86.1%)

213 (85.9%)

 Smoking

 No (never smoked)

102 (40.6%)

83 (33.5%)

 Ex-smoker

124 (49.4%)

135 (54.4%)

 Current

25 (10.0%)

30 (12.1%)

 Heart failure

 HFpEF (LVEF ≥ 50%)

35 (13.9%)

33 (13.3%)

 HFmrEF (LVEF 41–49%)

14 (5.6%)

16 (6.5%)

 HFrEF (LVEF ≤ 40%)

10 (4.6%)

7 (2.8%)

 Atrial fibrillation

 Paroxysmal

33 (13.1%)

31 (12.5%)

 Persistent

8 (3.2%)

9 (3.6%)

 Permanent

4 (1.6%)

11 (4.4%)

 Exercise capacity

 Peak oxygen consumption

 ml kg−1 min−1

18.7 (4.8)

18.6 (4.4)

 Percentage of predicted norm valuesa

82.2 (17.4)

81.6 (13.6)

 Level of education

 Low

8 (3.4%)

4 (1.7%)

 Medium

112 (47.5%)

106 (45.7%)

 High

116 (49.2%)

122 (52.6%)

 Technical competencies

 Having your own mobile device

 Yes

205 (81.7%)

195 (78.6%)

 No

33 (13.1%)

32 (12.9%)

 Usage of mobile applications

 Daily

153 (61.0%)

141 (56.9%)

 Weekly

21 (8.4%)

21 (8.5%)

 Less than weekly/never

64 (25.5%)

65 (26.2%)

 Handling of technical devices

 Rather easy

47 (18.7%)

30 (12.1%)

 Rather difficult

173 (68.9%)

167 (67.3%)

 Unknown

15 (6.0%)

29 (8.5%)

  1. Data are mean (s.d.) or n (%). The level of education was based on the International Standard Classification of Education 2011 according to the highest self-reported graduation and/or professional training.
  2. aBased on the normative data from the Study of Health in Pomerania (SHIP) study36.
  3. CCS, Canadian Cardiovascular Society; HFpEF, heart failure with preserved ejection fraction; HFmrEF, heart failure with mildly reduced ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction.